By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



One MedImmune Way

Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-398-0000 Fax: 301-398-9000


MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.

With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.

Key Statistics

Ownership: Public

Web Site: MedImmune
Employees: 3,000
Symbol: AZN


Company News
Investigational New Drug Application For WuXi PharmaTech Co., Ltd. MedImmune (AZN)'s Monoclonal Antibody Accepted For Review By CFDA 3/27/2015 6:21:17 AM
MedImmune (AZN) And Joslin Diabetes Center Announce New Research Collaboration Focused On Advancing Metabolic Disease Research 3/10/2015 8:25:25 AM
AstraZeneca PLC (AZN)'s MedImmune (AZN) Will Provide First-Year Funding for Seven NIST Postdoc Scientists in Unique R&D Deal 2/23/2015 6:16:44 AM
MedImmune (AZN) And The AstraZeneca PLC (AZN) Announce Partnership To Advance Protein Formulation Science 2/5/2015 2:45:29 PM
MedImmune (AZN) Release: First Patient Enrolled In The New Drugs 4 Bad Bugs Program 2/2/2015 11:20:39 AM
MedImmune (AZN) Establishes Three-Year Partnership With National Cancer Institute To Advance Oncology Research 1/21/2015 9:32:53 AM
MedImmune (AZN) Enters Licensing Agreement With Omnis Pharmaceuticals For Oncolytic Viruses In Immuno-Oncology 1/12/2015 11:51:57 AM
Tetragenetics, Inc. Collaborates With MedImmune (AZN) On Multi-Target Ion Channel Drug Discovery Program 1/7/2015 10:53:36 AM
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-HPV In Combination With MedImmune (AZN)'s MEDI4736 For The Treatment Of HPV-Associated Cancers 12/15/2014 7:24:48 AM
Immunocore And MedImmune (AZN) Win The SCRIP Award For Best Partnership Alliance 2014 12/10/2014 9:01:20 AM